Dr. Hollis Karoly, Exploring the Effects of Oral Cannabidiol on Blood Alcohol Level and Intoxication: Results from a Human Laboratory Study

September 2022

Dr. Hollis Karoly is an Assistant Professor at Colorado State University, Fort Collins, Colorado specializing in Clinical Psychology and Neuroscience with a specialization in addictive disorders. Her research aims to characterize neural, molecular and behavioral mechanisms underlying the etiology of alcohol use disorders, in an effort to inform treatment development. More specifically, Dr. Karoly is interested in how functional impairments along the microbiota-gut-brain-axis (MGBA; which refers to bidirectional interactions between gut microbes, endocrine, autonomic, enteric, immune and central nervous systems) may promote alcohol use behavior and serve as potential treatment targets. In recent years, her work has increasingly emphasized the role of the endogenous cannabinoid system – which is distributed heavily throughout the brain and gut – in the context of alcohol use disorders. Thus, Dr. Karoly is conducting several studies measuring the impact of phytocannabinoids (primarily cannabidiol [CBD] and tetrahydrocannabinol [THC]) on behavioral phenotypes related to alcohol use disorder (alcohol consumption, craving, intoxication) and on biomarkers across the MGBA (brain structure and function, peripheral inflammation, intestinal permeability, gut microbial composition). To this end, Dr. Karoly combines behavioral measures, molecular biology methods, neuroimaging and high throughput 16S ribosomal RNA gene sequencing to explore the impact of alcohol and cannabis on the MGBA and behavior. Because this work involves acute administration of various cannabis products, Dr. Karoly’s research also makes use of a Mobile Drug Administration Laboratory which adheres to federal guidelines restricting cannabis administration in academic research.

Previous Webinars

Tony P. George, MD, FRCPC

June 11, 2026 at 1 PM MDT

Understanding the links between cannabis use and mental illness: Implications for treatment

 

Dr. George is Professor of Psychiatry in the Temerty Faculty of Medicine at the University of Toronto (UofT), and Senior Scientist at the Centre for Addiction and Mental Health (CAMH). He received his B.Sc. (1988) and M.D. (1992) degrees from […]

Read More »

Jacob MacWilliams, Ph.D.

May 20, 2026 11:00AM MDT

Unlocking the mystery of a key hemp pest, cannabis aphid

Dr. Jacob MacWilliams is a research scientist in Dr. Punya Nachappa’s lab in the Agricultural Biology Department at Colorado State University. Jacob received his Ph.D. in Biochemistry and Molecular Biology at the University of California, Riverside focusing on cowpea aphid resistance in […]

Read More »

Shanna Bablonis, Ph.D.

Cannabis and Opioid Interactions: Human Laboratory Studies and Clinical Implications

May 14, 2026 1:00PM MDT

Shanna Babalonis, PhD is an associate professor in the University of Kentucky (UK) College of Medicine Department of Behavioral Science and Center on Drug and Alcohol Research. Her NIH-funded research focuses on clinical trials and human laboratory assessments of the abuse potential, […]

Read More »

Michael Petersen

Apr 15, 2026 11:00 AM Mountain Time

Trait Modifications in Cannabis Through Engineering and Editing

Michael Petersen has over 40 years of experience as a researcher and mentor in the plant biotech space. He worked for 10 years at Agracetus, a small startup in Wisconsin and then 20 years as a Senior Fellow with Monsanto. Mike stayed […]

Read More »